A share price of EyePoint Pharmaceuticals Inc [EYPT] is currently trading at $17.82, up 0.45%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The EYPT shares have gain 24.96% over the last week, with a monthly amount glided 60.83%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] stock has seen the most recent analyst activity on June 17, 2025, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $28. Previously, Citigroup started tracking the stock with Buy rating on January 07, 2025, and set its price target to $33. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $15 on August 28, 2024. JP Morgan initiated its recommendation with a Overweight and recommended $35 as its price target on January 22, 2024. Mizuho started tracking with a Buy rating for this stock on November 02, 2023, and assigned it a price target of $20. In a note dated April 21, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $33 on this stock.
EyePoint Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $3.91 and $17.82. Currently, Wall Street analysts expect the stock to reach $33 within the next 12 months. EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] shares were valued at $17.82 at the most recent close of the market. An investor can expect a potential return of 85.19% based on the average EYPT price forecast.
Analyzing the EYPT fundamentals
Trailing Twelve Months sales for EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] were 42.34M which represents -90.82% decline. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -5.16%, Pretax Profit Margin comes in at -4.86%, and Net Profit Margin reading is -4.86%. To continue investigating profitability, this company’s Return on Assets is posted at -0.82, Equity is -0.76 and Total Capital is -0.99. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.32 points at the first support level, and at 16.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.71, and for the 2nd resistance point, it is at 19.61.
Ratios To Look Out For
To put it in perspective, the Current Ratio for EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] is 7.18. Also, the Quick Ratio is 7.11, while the Cash Ratio stands at 2.48. Considering the valuation of this stock, the price to sales ratio is 34.84, the price to book ratio is 6.19.
Transactions by insiders
Recent insider trading involved Cormorant Asset Management, LP, Former 10% Owner, that happened on Dec 04 ’25 when 60000.0 shares were sold. Director, Lurker Nancy completed a deal on Dec 04 ’25 to sell 9300.0 shares. Meanwhile, Officer Lurker Nancy bought 9300.0 shares on Dec 04 ’25.
